Ritonavir

Canagliflozin

Dosage adjustment may be necessary.

No pharmaceutical opinion available for this interaction.

Mechanism

Ritonavir may increase the metabolism (UGT) and decrease the plasma concentration of Canagliflozin.

Ritonavir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Canagliflozin

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy.

Consider increasing the dose to 300 mg in patients who tolerate canagliflozin 100 mg QD and with CrCl ≥ 60ml/min.

Alternative solution(s)

Metformin, DPP-4 Inhibitors, GLP-1 Agonists

Monitor

Tests

Blood Sugar

Pharmacokinetic parameters

Comment

Ref #3184 : Co-administration of 600 mg rifampicin, a potent UGT inducer, and a single dose of canagliflozin 300 mg (after 8 days of once daily rifampicin 600 mg) resulted in a 51% and 28% decrease in repaglinide AUC and Cmax, respectively.

Reference
  • 3184
    Canagliflozin (Invokana), Janssen, Ontario, Canada, 7 nov. 2017.